MSX-122 (10 mg/kg, i.p.) reduces inflammation caused by carrageenan and lung fibrosis from bleomycin in mice. At 4 mg/kg, i.p., daily, MSX-122 inhibits metastasis in a breast cancer metastasis animal model, and at 10 mg/kg i.p., daily, it significantly reduces hepatic micrometastases^[1].

MSX-122, a partial antagonist of CXCR4, impedes the CXCR4/CXCL12 interaction with an IC50 of approximately 10 nM. It does not affect cAMP reduction mediated by the ligands CCR3/CCL5 and CCR5/CCL5. At 100 nM, MSX-122 strongly inhibits the invasion of 78% of MDA-MB-231 cells but does not affect T-tropic HIV infection or show activity in calcium flux assays^[1].